• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Modern chemotherapy for brucellosis in humans.人类布鲁氏菌病的现代化疗方法。
Rev Infect Dis. 1990 Nov-Dec;12(6):1060-99. doi: 10.1093/clinids/12.6.1060.
2
[Antibiotic treatment of brucellosis].[布鲁氏菌病的抗生素治疗]
Presse Med. 1994 Jun 25;23(24):1128-31.
3
Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.墨西哥布鲁氏菌分离株对莫西沙星、环丙沙星及其他用于治疗人类布鲁氏菌病的抗菌药物的敏感性。
Scand J Infect Dis. 2004;36(9):636-8. doi: 10.1080/00365540410020767.
4
Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.羊种布鲁氏菌体外抗菌药敏性与人类布鲁氏菌病复发率的相关性
Antimicrob Agents Chemother. 1986 Dec;30(6):958-60. doi: 10.1128/AAC.30.6.958.
5
Therapeutic options for human brucellosis.人类布鲁氏菌病的治疗选择。
Expert Rev Anti Infect Ther. 2008 Feb;6(1):109-20. doi: 10.1586/14787210.6.1.109.
6
In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis.环丙沙星、头孢曲松及其他五种抗菌药物对95株羊种布鲁氏菌的体外活性
J Antimicrob Chemother. 1986 Apr;17(4):459-61. doi: 10.1093/jac/17.4.459.
7
Epididymoorchitis due to Brucella mellitensis: a retrospective study of 59 patients.由羊布鲁氏菌引起的附睾睾丸炎:59例患者的回顾性研究
Clin Infect Dis. 2001 Dec 15;33(12):2017-22. doi: 10.1086/324489. Epub 2001 Nov 6.
8
In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance.1999 年至 2007 年埃及分离的布鲁氏菌属的体外抗生素药敏试验及可能存在利福平耐药的证据。
Ann Clin Microbiol Antimicrob. 2012 Aug 28;11:24. doi: 10.1186/1476-0711-11-24.
9
[Determination of in vitro susceptibilities of Brucella spp. strains against 11 different antibacterial gents isolated from blood cultures].[布鲁氏菌属菌株对从血培养物中分离出的11种不同抗菌药物的体外敏感性测定]
Mikrobiyol Bul. 2017 Jul;51(3):260-268. doi: 10.5578/mb.57362.
10
Brucella melitensis bacteremia in children: review of 62 cases.儿童布鲁氏菌病:62例病例回顾
J Chemother. 2003 Feb;15(1):76-80. doi: 10.1179/joc.2003.15.1.76.

引用本文的文献

1
Brucellosis: Bacteriology, pathogenesis, epidemiology and role of the metallophores in virulence: a review.布鲁氏菌病:细菌学、发病机制、流行病学及金属离子载体在毒力中的作用:综述
Front Cell Infect Microbiol. 2025 Jul 8;15:1621230. doi: 10.3389/fcimb.2025.1621230. eCollection 2025.
2
Clinical investigation and management of Brucella suis seropositive dogs: A longitudinal case series.猪布鲁氏菌血清阳性犬的临床调查和管理:一项纵向病例系列研究。
J Vet Intern Med. 2023 May-Jun;37(3):980-991. doi: 10.1111/jvim.16678. Epub 2023 May 9.
3
Antibiogram Screening and Detection of Virulence-Associated Genes in Species Acquired from Cattle in South Africa's Eastern Cape Province.
从南非东开普省牛群中分离的 种的抗生素药敏谱筛选和毒力相关基因检测。
Int J Environ Res Public Health. 2022 Feb 28;19(5):2813. doi: 10.3390/ijerph19052813.
4
Immunization with S19Δ Conferred Protection in Water Buffaloes against Virulent Challenge with Strain S544.用S19Δ免疫水牛可使其免受S544毒株的强毒攻击。
Vaccines (Basel). 2021 Dec 2;9(12):1423. doi: 10.3390/vaccines9121423.
5
Protein Biomarker Identification for the Discrimination of Field Isolates From the Rev.1 Vaccine Strain by MALDI-TOF MS.通过基质辅助激光解吸电离飞行时间质谱法鉴别Rev.1疫苗株田间分离株的蛋白质生物标志物
Front Microbiol. 2021 Oct 22;12:712601. doi: 10.3389/fmicb.2021.712601. eCollection 2021.
6
Bibliometric analysis of global research trends on male osteoporosis: a neglected field deserves more attention.男性骨质疏松症全球研究趋势的文献计量分析:一个被忽视的领域值得更多关注。
Arch Osteoporos. 2021 Oct 11;16(1):154. doi: 10.1007/s11657-021-01016-2.
7
Molecular characterization and antimicrobial susceptibility testing of clinical and non-clinical and isolates from Egypt.埃及临床和非临床分离株的分子特征及抗菌药敏试验
One Health. 2021 Apr 27;13:100255. doi: 10.1016/j.onehlt.2021.100255. eCollection 2021 Dec.
8
Worldwide research tendency and hotspots on hip fracture: a 20-year bibliometric analysis.全球髋部骨折研究趋势和热点:20 年文献计量分析。
Arch Osteoporos. 2021 Apr 17;16(1):73. doi: 10.1007/s11657-021-00929-2.
9
The current therapeutical strategies in human brucellosis.人布鲁氏菌病的当前治疗策略。
Infection. 2021 Oct;49(5):823-832. doi: 10.1007/s15010-021-01586-w. Epub 2021 Mar 1.
10
Build better bones with exercise (B3E pilot trial): results of a feasibility study of a multicenter randomized controlled trial of 12 months of home exercise in older women with vertebral fracture.运动促进骨骼健康(B3E 试验):多中心随机对照试验对老年椎体骨折女性进行 12 个月家庭运动干预的可行性研究结果。
Osteoporos Int. 2018 Nov;29(11):2545-2556. doi: 10.1007/s00198-018-4652-0. Epub 2018 Aug 8.

人类布鲁氏菌病的现代化疗方法。

Modern chemotherapy for brucellosis in humans.

作者信息

Hall W H

机构信息

Research Service (151), Veterans Affairs Medical Center, Minneapolis, Minnesota 55417.

出版信息

Rev Infect Dis. 1990 Nov-Dec;12(6):1060-99. doi: 10.1093/clinids/12.6.1060.

DOI:10.1093/clinids/12.6.1060
PMID:2267485
Abstract

The most effective, least toxic chemotherapy for human brucellosis is still undecided. In vitro, the antibiotics most active against Brucella include the tetracyclines, the aminoglycosides, the aminopenicillins, some cephalosporins, trimethoprim-sulfamethoxazole, erythromycin, rifampin, and some new fluorinated quinolones. Because Brucella species are facultative intracellular parasites, the penetration of drugs into and within phagocytes and phagosomes can be problematic and can best be studied in experimental animals or tissue cultures. In humans, the effectiveness of various regimens of chemotherapy has been compared best in acute bacteremic infections by assessment of the control of symptoms, bacteremia, complications, and relapses. The standard therapy against which all other therapies have been judged is a combination of tetracycline and streptomycin, which is almost universally effective but fails to prevent relapse in 10% of cases. A combination of oral doxycycline and rifampin is convenient and currently popular; it is highly effective, with an average relapse rate of only 8.4%. Trimethoprim-sulfamethoxazole is less effective in controlling bacteremia and other manifestations: in collected series, 5.7% of cases did not respond and 12% relapsed. Drug-resistant Brucella strains are rarely a cause of therapy failure. Localized brucellosis poses special problems, often requiring surgery in addition to prolonged combined chemotherapy.

摘要

治疗人类布鲁氏菌病最有效、毒性最小的化疗方案仍未确定。在体外,对布鲁氏菌活性最强的抗生素包括四环素类、氨基糖苷类、氨基青霉素类、一些头孢菌素、甲氧苄啶 - 磺胺甲恶唑、红霉素、利福平以及一些新型氟喹诺酮类。由于布鲁氏菌属是兼性细胞内寄生虫,药物进入吞噬细胞和吞噬体及其在其中的渗透可能存在问题,最好在实验动物或组织培养中进行研究。在人类中,通过评估症状、菌血症、并发症和复发的控制情况,在急性菌血症感染中能最好地比较各种化疗方案的有效性。所有其他疗法与之比较的标准疗法是四环素和链霉素联合使用,该疗法几乎普遍有效,但仍有10%的病例无法预防复发。口服强力霉素和利福平联合使用方便且目前很流行;它非常有效,平均复发率仅为8.4%。甲氧苄啶 - 磺胺甲恶唑在控制菌血症和其他表现方面效果较差:在收集的系列病例中,5.7%的病例无反应,12%复发。耐药布鲁氏菌菌株很少是治疗失败的原因。局限性布鲁氏菌病带来特殊问题,通常除了长期联合化疗外还需要手术治疗。